Nicotinamide mononucleotide (NMN) is at the center of a legal dispute as the Natural Products Association (NPA) has filed a lawsuit against the U.S. Food and Drug Administration (FDA) over its classification as a dietary supplement. This lawsuit follows a recent court ruling that granted a stay in the proceedings, allowing the FDA additional time to evaluate a citizen petition concerning NMN’s status. The ruling provides a temporary pause in legal actions while the government has indicated it will not pursue enforcement actions against NMN dietary supplements under certain conditions.
The NMN Controversy Background
The NPA and the FDA are engaged in a dispute over the legality of NMN, a health ingredient currently being researched by Metro International Biotech LLC as a potential new drug. The company claimed to have initiated substantial clinical trials under an investigational new drug application (IND) to explore NMN’s effectiveness in treating various medical conditions, including Alzheimer’s disease, Friedreich ataxia, and kidney disease.
In March 2023, the NPA and the Alliance for Natural Health (ANH) submitted a petition urging the FDA to reconsider its position or exercise enforcement discretion. However, despite this petition, the FDA has yet to provide a definitive response, citing “competing agency priorities” that have hindered its ability to meet the 180-day decision timeline.
The NPA’s lawsuit challenges the FDA’s interpretation of the Dietary Supplement Health and Education Act (DSHEA), arguing that the agency has misapplied the “Drug Exclusion Clause” by wrongfully classifying NMN as a substance that cannot be marketed as a dietary supplement. According to the NPA, this interpretation threatens not only NMN but also poses risks to many other dietary ingredients in the market.
Recent Developments: Court Grants Stay
On October 24, 2024, a federal court issued a stay, effectively pausing legal proceedings while the FDA reviews the citizen petition regarding NMN. The agency is expected to respond by July 31, 2025. In a positive turn, an FDA spokesperson indicated that the agency does not plan to pursue enforcement actions against NMN dietary supplements under certain conditions. This implies that NMN products may continue to be sold without immediate regulatory concerns, as long as they comply with existing regulations.
Positive Outlook for the NMN Market
These developments significantly relieve consumers worldwide who rely on NMN products for their health benefits. Dr. Jianjun Yu from EffePharm remarked: “At EffePharm, we are committed to delivering clinically proven, high-quality NMN ingredients. As the dispute continues and we await the FDA’s response, we remain optimistic that our unwavering dedication will keep UTHEVER® NMN shining bright as a trusted health option.”
What’s Next?
The ongoing situation surrounding NMN marks a pivotal moment for dietary supplements in the United States. With legal actions on hold and the FDA showing signs of a more flexible stance, the outlook for NMN products appears increasingly steady. One thing is clear: the health NMN’s health benefits and promise are acknowledged, securing its place as a viable choice for consumers worldwide.
References
Long, J. (2024a, August 29). FDA faces new lawsuit from NPA over anti-aging ingredient NMN. Supplysidesj.com. https://www.supplysidesj.com/supplement-regulations/fda-faces-new-lawsuit-from-npa-over-anti-aging-ingredient-nmn
Long, J. (2024b, October 25). FDA telegraphs enforcement strategy against NMN supplements amid NPA lawsuit. Supplysidesj.com. https://www.supplysidesj.com/supplement-regulations/fda-telegraphs-enforcement-strategy-against-nmn-supplements-amid-npa-lawsuit
Long, J. (2024c, October 31). Judge pauses court case against FDA over NMN supplements. Supplysidesj.com. https://www.supplysidesj.com/supplements/judge-pauses-court-case-against-fda-over-nmn-supplements
